• +1-646-491-9876
    • +91-20-67278686

    Search

    Nephrotic Syndrome Pipeline Review H1 2017

    Nephrotic Syndrome Pipeline Review H1 2017

    • Report Code ID: RW0001799300
    • Category Pharmaceuticals
    • No. of Pages 38
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Nephrotic Syndrome - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Nephrotic Syndrome - Pipeline Review, H1 2017, provides an overview of the Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline landscape.

    Nephrotic syndrome is a kidney disorder that causes body to excrete too much protein in your urine. Nephrotic syndrome is usually caused by damage to the clusters of small blood vessels in kidneys that filter waste and excess water from blood. Symptoms include severe swelling (edema) , foamy urine and weight gain due to excess fluid retention. Risk factors include diabetes, lupus, amyloidosis, HIV, hepatitis B, hepatitis C, malaria, certain medications (non-steroidal anti-inflammatory drugs and drugs used to fight infections) .

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Nephrotic Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nephrotic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Nephrotic Syndrome (Genito Urinary System And Sex Hormones) .
    - The pipeline guide reviews pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Nephrotic Syndrome (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Nephrotic Syndrome (Genito Urinary System And Sex Hormones)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Nephrotic Syndrome (Genito Urinary System And Sex Hormones) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Nephrotic Syndrome (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Nephrotic Syndrome - Overview
    Nephrotic Syndrome - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Nephrotic Syndrome - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Nephrotic Syndrome - Companies Involved in Therapeutics Development
    AbbVie Inc
    Asahi Kasei Pharma Corp
    Bristol-Myers Squibb Company
    Orbis Biosciences Inc
    Retrophin Inc
    Nephrotic Syndrome - Drug Profiles
    abatacept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    atrasentan hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cosyntropin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mizoribine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prednisone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Proteins to Inhibit Complement C3 for Nephrosis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SP-20104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nephrotic Syndrome - Dormant Projects
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Nephrotic Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Nephrotic Syndrome - Pipeline by AbbVie Inc, H1 2017
    Nephrotic Syndrome - Pipeline by Asahi Kasei Pharma Corp, H1 2017
    Nephrotic Syndrome - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Nephrotic Syndrome - Pipeline by Orbis Biosciences Inc, H1 2017
    Nephrotic Syndrome - Pipeline by Retrophin Inc, H1 2017
    Nephrotic Syndrome - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Nephrotic Syndrome, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AbbVie Inc
    Asahi Kasei Pharma Corp
    Bristol-Myers Squibb Company
    Orbis Biosciences Inc
    Retrophin Inc

    Request for Sample

    Report Url http://www.reportsweb.com//nephrotic-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//nephrotic-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//nephrotic-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments